A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia

Cancer

Volumn 95, Issue 3, 2002, Pages 581-587

  Weiss, Mark A ^a   Aliff, Timothy B ^a   Tallman, Martin S ^b   Frankel, Stanley R ^c   Kalaycio, Matt E ^d   Maslak, Peter G ^a   Jurcic, Joseph G ^a   Scheinberg, David A ^a   Roma, Todd E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adult acute lymphoblastic leukemia; Cytarabine; Idarubicin; Recurrent; Refractory

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; IDARUBICIN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONVALESCENCE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INFECTION; MALE; NEUTROPHIL; PRIORITY JOURNAL; RECURRENT CANCER; SALVAGE THERAPY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COGNITION; CONJUNCTIVITIS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HEART; HEMATEMESIS; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036682235     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10707     Document Type: Article

References (31)

1. Treatment of acute lymphoblastic leukemia. Thirty years' experience at St. Jude Children's Research Hospital
2. Acute lymphoblastic leukemia-progress in children, less in adults
3. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811
4. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
5. Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols
6. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy
7. Combination chemotherapy for hematologic relapse in adult acute lymphoblastic leukemia (ALL)
8. A Phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia
9. A Phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia
10. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome
11. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients
12. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia
13. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)
14. Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia
15. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults
16. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience
17. Acute leukemias
18. Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: A report from the Children's Cancer Group
19. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone
20. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival
21. A Phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
22. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia
23. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia
24. Treatment of adults with acute lymphoblastic leukemia in first bone marrow relapse: Results of the ALL R-87 protocol
25. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia
26. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia
27. Daunorubicin, vincristine, and prednisone for remission induction in patients with acute lymphoblastic leukemia in relapse
28. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia
29. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
30. Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol WR1065, in vitro